CD4 and tuberculosis: However, IRIS events are rarely fatal and many studies, including three clinical trials, namely SAPiT, STRIDE, and CAMELIA, have unequivocally demonstrated the survival benefits of early ART in HIV-infected TB patients, especially in those with CD4 counts <50/μL [29,30,31,32,33].